Market Overview

UPDATE: Jefferies Cuts PT to $3.50 on Unilife Corporation on Deal Delays

Related UNIS
Unilife Signs Long-Term Commercial Supply Agreement For Use of Depot-ject Delivery System With Approved Ocular Injection Drug
Unilife And Flextronics Enter Into Global Strategic Alliance

Jefferies maintained Unilife Corporation (NASDAQ: UNIS) with a Buy rating and lowered the price target from $5.00 to $3.50.

Jefferies commented, "Unilife's 2Q results did little to sway the balance of the company's outlook. The company reiterated that more than a dozen deals will contribute revs in CY13, but details were light and the CEO was noticeably absent from the call. Meanwhile, cash burn is high and despite recent equity raises dry powder is limited. It is tenuous but we stay at Buy on the promise of a substantial ramp should deals mature."

Unilife Corporation closed at $2.28 on Monday.

Latest Ratings for UNIS

Oct 2014Ladenburg ThalmannUpgradesNeutralBuy
Sep 2014Ladenburg ThalmannDowngradesBuyNeutral
Sep 2014JefferiesMaintainsBuy

View More Analyst Ratings for UNIS
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (UNIS)

Around the Web, We're Loving...

Get Benzinga's Newsletters